# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $85 to ...
RBC Capital analyst Shagun Singh maintains Globus Medical (NYSE:GMED) with a Outperform and raises the price target from $76...
Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Hold and raises the price target from...
Wells Fargo analyst Vik Chopra upgrades Globus Medical (NYSE:GMED) from Equal-Weight to Overweight and raises the price targ...
Needham analyst David Saxon reiterates Globus Medical (NYSE:GMED) with a Hold.
Globus Medical (NYSE:GMED) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.68 by...